Research programme: inflammation and wound therapeutics - ITL Pharma

Drug Profile

Research programme: inflammation and wound therapeutics - ITL Pharma

Alternative Names: Loopin

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator ITL Pharma
  • Class
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Wounds

Highest Development Phases

  • Research Inflammation; Wounds

Most Recent Events

  • 21 Feb 2017 Research programme: inflammation and wound therapeutics - ITL Pharma is available for licensing as of 21 Feb 2017. http://www.itlpharmaceuticals.com/investors.html
  • 21 Feb 2017 Early research in Inflammation in USA (unspecified route)
  • 21 Feb 2017 Early research in Wounds in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top